Re:Compass Pathways' Phase IIb psilocybin trial shows reduce...
by JohnJamesRambo on Tuesday November 09, 2021 @07:28PM
(#29169507)
This sounds pretty crappy right? If I'm understanding the numbers, 25% response is about like what we get with a placebo in most studies if my memory is correct.
It sounds like they were tripping balls on 25 mg, so this is definitely in active placebo range.
From my memory:
Placebo is about 25%.
Antidepressants about 35% response rate.
Active placebo of something like atropine which makes you feel weird but isn't an antidepressant has about a 35% response rate.
https://blogs.scientificamerican.com/cross-check/are-antidep...
They noticed a response to psilocybin+therapy in about 20-25% of patients depending on the criteria for “sustained response”:
> The protocol-defined sustained response* up to week 12 was double, with 20.3% of patients in the 25mg group
It’s also notable that about 5% of the psilocybin receivers experienced severe adverse events including suicidal ideation:
> There were 12 patients who reported treatment-emergent serious adverse events (TESAEs). These TESAEs included suicidal behaviour, intentional self-injury, and suicidal ideation